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Mutations of Runx2 [also known as Core-binding factor
a1 (Cbfa1), PEBP2A1, and AML3) have been identiﬁed
as being responsible for cleidocranial dysplasia (CCD)
(Fig. 1) (1). This is an autosomal-dominant inherited
disorder characterized by patent fontanelles, wide cranial
sutures, frontal bossing, hypoplasia of the clavicles, short
stature, ectopic and delayed eruption of teeth, supernu-
merary teeth, and other skeletal anomalies. Gene
knockout experiments have produced similar skeletal
phenotypes in mice (2).
RUNX2 is an osteoblast-speciﬁc transcription factor
necessary for the diﬀerentiation of pluripotent mesen-
chymal cells to osteoblasts (3). The presence of RUNX2
in fully diﬀerentiated cells supports the concept that
RUNX2 is also required in maintaining fully functional
cells, at least in bone (3–5).
RUNX2 has also been identiﬁed as essential for tooth
formation (4, 6). Dental abnormalities seen in CCD
patients (7, 8) may be a direct result of RUNX2 dys-
function in tooth-forming cells. The dental abnormalities
in CCD suggest an important role for RUNX2 during
formation of the dentition.
The Runx2 gene is 220 kb long (9) and contains eight
exons (5, 10, 11). It belongs to the runt domain (RUNX)
family of genes. These genes, named Runx1, -2 and -3,
exhibit a high amino acid homology. Their protein
products form a heterodimer with core-binding factor b
(CBFb) (12).
CBFb is required for the eﬃcient function of RUNX2
in skeletal development (13), allosterically enhancing
DNA binding by RUNX proteins at the runt homology
domain (RHD) (14). Furthermore, it plays an important
role in stabilizing RUNX proteins against proteolytic
degradation by the ubiquitin–proteasome system (15).
Runx2 and bone
Bone tissue consists of hydroxyapatite crystals and var-
ious kinds of extracellular matrix (ECM) proteins,
including type I collagen, osteocalcin, osteonectin, oste-
opontin, bone sialoprotein (BSP), and proteoglycans
(16, 17). These bone matrix proteins are secreted and
deposited by polarized mature osteoblasts, which are
aligned on the bone surface (18). The precise roles of
matrix proteins in the formation of bone are not fully
elucidated (19, 20). The formation of hydroxyapatite
crystals is also regulated by osteoblasts.
The establishment of Runx2 null mice clearly demon-
strated that this transcription factor is essential for
osteoblast diﬀerentiation, as these mice had no bone
tissue, osteoblasts or osteoclasts, despite normal cartila-
ginous skeletal patterning. Chondrocyte maturation,
however, is perturbed as a consequence (2, 21).
Runx2 is also active in mature osteoblasts. Mature
mice, in whom active RUNX2 levels have been reduced,
exhibit decreased expression of the genes encoding the
main bone matrix proteins, BSP, osteocalcin, osteopon-
tin and collagen type I (4). These genes are regulated via
the RUNX2-binding sites in the proximal promoter
segments of the respective genes (14).
RUNX2 has thus been shown to be essential for nor-
mal bone formation, with perturbation of bone forma-
tion if the levels are insuﬃcient. Overproduction will also
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aﬀect bone formation. Osteoblasts taken from non-syn-
dromic synostosed sutures in children exhibited an
increase in Runx2 expression, possibly explaining the
enhanced proliferation and bone-forming ability of these
cells (22). However, adult transgenic mice overexpressing
Runx2 showed osteopenia with a decrease in bone min-
eral density. This was attributed to reduced osteoblast
maturation, but also to enhanced receptor activator of
nuclear factor kappa b ligand (RANKL) and matrix
metalloproteinase-13 (MMP-13) production with
enhanced osteoclastogenesis (23). Neonatal transgenic
mice showed maturational blockage of osteoblasts, but
did not show enhanced osteoclastogenesis, possibly
because of the diﬀerent ages of the experimental mice
(24). The results of these experiments are consistent with
evidence that Runx2 is regulated, in part, through a
negative feedback loop by activity of the RUNX2 pro-
tein on its own promoter, to control variations in gene
expression and function during osteogenesis (25).
Runx2 expression decreases with age. This may be one
possible explanation for impaired osteoblast function
and reduced bone formation with aging (26).
RUNX2 is aﬀected by a diversity of signaling path-
ways. Binding of ECM proteins to cell-surface integrins,
mechanical loading, ﬁbroblast growth factor 2 (FGF2),
parathyroid hormone (PTH), and bone morphogenetic
proteins (BMP), all inﬂuence RUNX2-dependent tran-
scription. These post-translational changes act via the
mitogen-activated protein kinase (MAPK) and protein
kinase A and C (PKA, PKC) pathways, activating
RUNX2 by phosphorylation (27–29) (Fig. 2). Further
control of the RUNX2 molecule occurs through the
counterplay of acetylation and ubiquitinization (29–31)
(Fig. 3) The Runx2 gene, in fact, plays a central role in
co-ordinating multiple signaling pathways aﬀecting
osteoblast diﬀerentiation.
A species-speciﬁc diﬀerence in action may, however,
exist. Osteoblast diﬀerentiation in rodents is associated
with an increase in RUNX2 production. However, in
human bone marrow stem cells, enhanced transactiva-
tion activity occurs with no change in Runx2 mRNA or
protein levels. This activity has been ascribed to post-
translational phosphorylation of key residues in the
RUNX2 protein (32).
RUNX2 domains
RUNX2 binds to the core binding factor site, also
known as the osteoblast-speciﬁc cis-acting element 2
(OSE2) (33), which is found in the promoter regions of
all the major osteoblast-characteristic genes, such as
osteocalcin, type I collagen, BSP, osteopontin, MMP-13,
and alkaline phosphatase. Together with other factors,
such as activator protein 1 (AP-1) and mothers against
decapentaplegic homolog (SMADs), it controls their
expression (34, 35). The RHD is responsible for the
DNA-binding properties of RUNX2 (Fig. 4).
Three transactivation domains and one major repres-
sion domain have been identiﬁed in the RUNX2 protein
(36). The ﬁrst transactivation domain is located in the
N-terminal 19 amino acids of the protein, while the
second is located in the glutamine/alanine (Q/A) domain.
In the latter, transactivation depends on a stretch of
29 glutamine residues. Deletion of the alanine stretch
does not aﬀect transactivation; however, expansion has a
repressive function (1), and expansion may also play a
role in nuclear localization (37).
The third activation domain is present in the N-ter-
minal portion of the proline/serine/threonine (PST)-rich
domain. A mutation in this region has been shown to
cause a failure to interact with SMADs, reducing the
response of osteoblasts to the Transforming growth
factor-b/Bone morphogenetic protein (TGF-b/BMP)
signaling pathway (38). This region has also been shown
to interact with the co-activator molecule, p300, aﬀecting
expression of the osteocalcin gene (39). This action is
independent of the acetyltransferase activity of p300,
which protects RUNX2 from degradation by SMAD
ubiquitin regulatory factor (SMURF)-mediated ubiqui-
tination and also increases the transactivation potential
of RUNX2 (31).
Fig. 1. A 12-yr-old female patient with cleidocranial dysplasia. (A) Lateral skull radiograph showing a wormian bone in the temporal
suture region and a hypoplastic maxilla. (B) Panoramic radiograph showing supernumerary and unerupted teeth, some of which are
ectopic. Typically, the lower permanent central incisors and all four ﬁrst permanent molars have erupted.
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The C-terminal part of the PST domain is a repression
domain (36, 40). The terminal ﬁve amino acids (the
VWRPY motif) are highly conserved and may bind the
corepressor proteins of the transducin-like enhancer of
split (TLE) or Groucho-related genes (Grg) family (41).
The down-regulation of TLE/Grg expression during
osteoblast diﬀerentiation is a potential mechanism for
relief of Runx2 repression during cell diﬀerentiation (42).
Other parts of the molecule have been shown to react
with other corepressors, such as histone deacetylases
(HDAC) (40), SIN3 (43), and yes-associated proteins
(YAP) (44) (Table 1 and Fig. 4). A review of RUNX2
corepression was made by Westendorf (45).
RUNX2 is imported to the nucleus after transcription
and must bind to speciﬁc regions of the nuclear matrix to
eﬀect transcriptional control (53), colocalizing with
co-activators such as SMADs (35) and RNA poly-
merases, at nuclear sites that support RNA synthesis (54).
This function is eﬀected by the nuclear matrix target-
ing signal (NMTS) region, a 38 amino acid segment
situated between the RHD and PST domains (55). Point
mutations in the NMTS region have been shown to aﬀect
the intranuclear localization of RUNX2, possibly
aﬀecting its interaction with target genes that are
involved in osteolytic activity (38, 56).
The interaction of transcription factors with cellular
signal transducers at particular points in the nuclear
matrix may partly explain the tissue-speciﬁc action of the
RUNX proteins and of transcription factors in general.
RUNX2 isoforms
RUNX2 has two major N-terminal isoforms, whose
transcription from the Runx2 gene is separately regulated
by either a proximal promoter or a distal promoter
(Fig. 5) (10). The product of the proximal promoter
starts with the amino acid sequence, MRIPVD, and is
known as Type I, PEBP2A or P56. That of the distal
promoter product starts with the amino acid sequence,
MASNSL, and is known as Type II, Til-1 or P57. OSF2
(Type III) is a splice variant of Type II, present only in
the mouse. It starts with the sequence MLHSPH, and its
function is similar to the Type II isoform. It is not
essential for optimal transcriptional activation (57), and
it may play a species-speciﬁc role in the regulation of
transcription (10).
Fig. 3. Bone morphogenetic proteins (BMP) and transforming
growth factor-b (TGF-b) act on P300 to acetylate (Ac)
RUNX2, protecting it from degradation via the ubiquitin
pathway. Histone deacetylases (HDACs) deacetylate RUNX2,
accelerating its degradation. SMURF, SMAD ubiquitin regu-
latory factor.
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Fig. 2. Multiple signaling pathways converge on RUNX2 to
initiate osteoblast diﬀerentiation. BMP2, Bone Morphogenic
Protein 2; ECM, Extracellular Matrix; FGF2, Fibroblast
Growth Factor 2; AP-1, Activator Protein 1; ERK, Extra-
cellular signal related kinase; FAK, Focal adhesion kinase; Fos,
Oncogene Fos; Fra, Fos related antigen; G, G alpha protein;
Jun, Oncogene Jun; MEK1/2, Mitogen activated protein ki-
nase/Extracellular signal related kinase1/2; OSE2, Osteoblast
Speciﬁc Element 2; Osx, Osterix; PTH, Parathyroid hormone;
PTHR, Parathyroid hormone related protein; Raf, Oncogene
Raf; Ras, Retrovirus associated DNA sequences; RTK,
Receptor Tyrosine Kinase; SBE, SMAD binding element;
Smad, Mothers against decapentaplegic protein. Modiﬁed after
Franceschi RT, Xiao G. J. Cell Biochem. Vol.88, 3 Pages: 446-
454. Copyright  2003 Wiley-Liss, Inc., A Wiley Company.
Reprinted with permission of Wiley-Liss, Inc., a subsidiary of
John Wiley & Sons, Inc.
Fig. 4. Distribution of the diﬀerent domains of the RUNX2
protein. The sites of interaction with various corepressor mol-
ecules are also shown. AD, transactivation domain; HDAC,
histone deacetylase; SIN3A, SIN3A protein; NMTS, nuclear
matrix targeting signal; PST, proline/serine/threonine rich do-
main; Q/A, glutamine/alanine-rich domain; RD, repression
domain; RUNT, Runt homology domain; TLE, transducin-like
enhancer of split; VRWPY, conserved repression signal; YAP,
yes-associated protein.
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The presence of multiple isoforms of the Runx2 gene
product is consistent with other members of the Runx
transcription family, including Runx1 and Runx3, that
exist as multiple isoforms with diﬀerent transactivation
potentials (58).
Type I and Type II isoforms diﬀer functionally, but
both are crucial in bone development. Type I is expressed
ubiquitously in both non-osseous mesenchymal tissues
and on osteoblast progenitor cells. It plays an important
role in a wide range of cellular diﬀerentiation events and
its expression is not aﬀected by the diﬀerentiation status
of the cell. In terms of intramembraneous bone forma-
tion, it probably is involved in the initial commitment
steps and continues to exert its eﬀects to the ﬁnal dif-
ferentiation of osteoblasts.
Type II expression is increased during osteoblast dif-
ferentiation and is induced as a response to BMP2,
suggesting that it is necessary for the maintenance of the
osteoblast phenotype and that Type I may have a regu-
latory role (Fig. 6) (59).
In contrast to the ﬁndings of Ducy et al. (3) and Xiao
et al. (10), Harada et al. (60) found all three isoforms to
be present in the bones of adult mice and concluded that
all three are involved in stimulating osteoblast diﬀeren-
tiation, exerting diﬀerent functions in the process of
diﬀerentiation depending on the cell type and the
Table 1
Known co-activators and corepressors of RUNX2. CBFB, core binding factor subunit B; GR65, Groucho related gene 5; HDAC3, histone
decetylase3; HDAC5, histone decetylase 5; HDAC6, histone decetylase 6; MORF, monocytic leukemia zinc ﬁnger protein-related
factor; pRb, retinoblastoma 1; Sin3A, Sin3 protein; TAZ, tafazzin; TLE/GROUCHO, transducin-like enhancer of split/Groucho related
genes; TWIST, Twist protein; YAP1, yes associated protein 1
Protein Reference Class Function
CBFB Yoshida et al. (13) Co-activator Enhances DNA binding of RUNX2
GRG5 Wang et al. (46) Co-activator Dominant-negative inhibitor of larger TLE proteins
HDAC3 Schroeder et al. (47) Corepressor Blocks RUNX2 dependent transcription
HDAC4 Vega et al. (48) Corepressor Prevents DNA binding
HDAC6 Westendorf et al. (40) Corepressor Deacetylation of histones
MORF Pelletier et al. (49) Co-activator Potentiates RUNX2 dependent transcription
MOZ Pelletier et al. (49) Co-activator Potentiates RUNX2 dependent transcription
SIN3A Fenrick et al. (43) Corepressor Alters subnuclear localization
p-300 Jeon et al. (31),
Sierra et al. (39)
Co-activator Acetylation of RUNX2/potentiates Vitamin D actions
pRb Thomas et al. (50) Co-activator Potentiates RUNX2 dependent transactivation
TAZ Cui et al. (51) Co-activator Potentiates RUNX2 dependent transactivation
TLE/GROUCHO McLarren et al. (41)
Javed et al. (42)
Corepressor Colocalizes at subnuclear level
TWIST Bialek et al. (52) Corepressor Prevents DNA binding of RUNX2
YAP1 Zaidi et al. (44) Corepressor Colocalizes at subnuclear level
Fig. 5. Diagram of the Runx2 promoter region. The P2 pro-
moter drives expression of the Type I isoform and is associated
with cell proliferation. The P1 promoter drives expression of the
Type II variant, associated with commitment to a calciﬁed tis-
sue line. A mini-intron separates Exon 0 from exon )1. Tran-
scription from this site produces the Type III variant, which has
similar properties to Type II but is found only in mice.
A, arginine; D, aspartic acid; H, histidine; I, isoleucine; L,
leucine; M, methionine; N, asparagine; P, proline; R, arginine;
S, serine; V, valine.
Fig. 6. Fibroblast growth factor 2 (FGF2) stimulates produc-
tion of the Type 1 isoform from the P2 promoter to initiate cell
commitment and proliferation. Bone morphogenetic protein 2
(BMP2), produced by these cells, acts via distal-less homeobox
5 (DLX5) on the distal P1 promoter to produce the Type 2
isoform, which encourages maturation of the osteoblast and
exit from the cell cycle. The action of DLX5 is antagonized by
muscle segment homeobox 2 (MSX2). Information derived
from Bannerjee et al. (59), Choi et al. (64) and Lee et al. (65).
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downstream gene promoter. Because production of the
Type II isoform is restricted to later events of cell dif-
ferentiation, being found only in pre-osteoblasts and
osteoblasts, its contribution is probably more speciﬁc in
the ﬁnal step into osteoblast diﬀerentiation and is
necessary for osteoblast maturation and skeletogenesis
(61, 62). However, the expression pattern and function of
both isoforms is not very diﬀerent in the later stages of
osteoblast diﬀerentiation (63).
The expression of Type I Runx2 is stimulated by
FGF2. This commits precursor cells to the osteoblast
lineage and permits cellular proliferation. Runx2 Type I
stimulates production of BMP2 and this, in turn, aﬀects
Runx2, its eﬀect being mediated by distal-less homeobox
5 (DLX5) (64). Lee et al. (65) found that DLX5 specif-
ically transactivates the Runx2 distal (P1) promoter in
committed osteoblasts and that its action is antagonized
by MSX2 (Fig. 6).
The pattern of isoform expression may be diﬀerent in
tooth tissue, with a high expression of Type I and weak
expression of Types II and III in the ameloblast and
odontoblast layers of neonatal mouse incisors (66).
However, Types II/III have been shown to be indis-
pensable for tooth germ development past the bud stage
and they play a role in the diﬀerentiation of ameloblasts
and odontoblasts, which is necessary for transcription of
dentine matrix protein 1 (DMP1), dentine sialoprotein
(DSPP), amelogenin (AMGN), and ameloblastin
(AMBN) in cultured mouse mandibles (67).
Dual translational control of Runx2, via both the
internal ribosomal entry site (IRES) and cap-dependent
mechanisms, exists for the P1 and P2 promoters. This
provides another level of control of RUNX2 isoforms
and may be a means to ﬁne-tune Runx2 expression
across a wide range of cellular conditions where the
amount of Runx2 gene products may be an important
determinant of their biological eﬀects (68).
Further isoforms of RUNX2 exist as a result of
alternative splicing. This also is consistent with ﬁndings
for other RUNX factors and may explain the diﬀerent
spatiotemporal patterns of expression of the gene (10, 58,
69, 70). The timing of expression of diﬀerent RUNX2
isoforms, in conjunction with other transcription factors
and depending on the level of diﬀerentiation of the cell,
may well serve as a method of control of bone and tooth
formation.
Runx2 and osteoclastogenesis
Overexpression of Runx2 increases osteoblast number
but inhibits their terminal maturation, resulting in
accumulation of less mature osteoblasts and consequent
osteopenia (24). Osteoclastogenesis is increased, possibly
by the increased production of RANKL and MMP-13
(two factors involved in bone formation–resorption
coupling) by the immature osteoblasts (23).
Osteoprogenitor cells have greater potential to support
osteoclast development than more diﬀerentiated cells
(71). Osteoclastogenesis is strongly induced by undiﬀer-
entiated stromal marrow cells, which produce high
RANKL levels. As maturation proceeds, RANKL levels
drop and those of its antagonist, osteprotegerin (OPG),
rise (72). The stimulus to osteoclastogenesis is reduced
accordingly and the diﬀerentiated osteoblasts proceed to
the formative phase of bone formation.
The precise role of RUNX2 in osteoclast regulation is
controversial. Opg is strongly expressed in Runx2–/–
calvarial cell lines, whereas Rankl is not (73, 74). How-
ever, RUNX2-binding elements are present in the pro-
moter region of the Opg gene. RUNX2 increases the
activity of the Opg promoter, suggesting that RUNX2
regulates osteoclastogenesis by inducing the expression
of Opg (75). TGF-b inhibits bone resorption by induc-
tion of Opg and its eﬀects are mediated by RUNX2 and
SMADs (76).
A RUNX2-binding site is present on the mouse and
human Rankl promoter (77), but RUNX2 failed to sti-
mulate the transcriptional activity of the promoter
region of the Rankl gene, showing that that RUNX2
possibly does not regulate Rankl in the same manner as
other known targets (78). However, RUNX2 induced
Rankl expression and suppressed Opg expression in the
presence of 1,25(OH)2D3 (74). On the other hand, forced
production of soluble RANKL was found to be insuﬃ-
cient for the complete rescue of osteoclast diﬀerentiation
in Runx2–/– mice, suggesting the presence of another
requirement for osteoclast diﬀerentiation. Also,
treatment of RUNX2-deﬁcient calvarial cells with
1,25(OH)2D3, aﬀected both Rankl and Opg expression
and induced osteoclastogenesis, showing that expression
of Rankl and Opg, and initiation of osteoclastogenesis,
may be induced via alternative pathways (79).
Colony-stimulating factor 1 (CSF-1) and RANKL are
widespread; however, osteoclasts are conﬁned to calciﬁed
tissue. The addition of CSF-1 and RANKL to serum-
free cell cultures produced no osteoclasts (80). This
suggests the existence of other factors or ECM proteins,
possibly induced by RUNX2 in osteoblasts, which are
required for osteoclast diﬀerentiation.
RUNX2 in odontogenesis
In the developing mammalian tooth, the cranial neural
crest-derived dental mesenchyme consists of the dental
papilla and dental sac. The dental papilla gives rise to
dental pulp and odontoblasts; the dental sac gives rise
to the periodontium, including the osteoblasts that
contribute to the alveolar process. The alveolar process
is a specialized intramembranously formed bone that
provides the primary support structure for the denti-
tion.
The expression of Runx2 in both the dental papilla
and dental sac suggests a potential involvement of
this gene in the diﬀerentiation of odontoblasts and
osteoblasts lining bone in the periodontal space (6,
81). Mice deﬁcient in RUNX2 exhibit an arrest of
molar tooth development at the early cap stage, sug-
gesting a requirement for RUNX2 in the progression of
tooth development from the cap stage to the bell stage
(6).
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In mouse embryonic mandibular ﬁrst molar tooth
germs, Runx2 expression is initiated by FGF produced
by the odontogenic epithelium, shortly after com-
mencement of epithelial thickening, and is followed by
expression of RANKL in the early alveolar bone ossiﬁ-
cation centers and that of its receptor, receptor activator
of nuclear factor kappa B (RANK) and OPG in tooth
bud epithelium and mesenchyme. Thus, Runx2 is not
involved in the initiation of tooth formation, but is
intimately involved in regulating the expression of
mesenchymal molecules that act reciprocally on the
epithelium to control the histo- and morpho-diﬀerenti-
ation of the enamel organ (6, 82, 83).
Runx2–/– mouse molars show arrested development at
the bud stage, whereas incisors, which develop earlier,
progress to the bell stage and show dentine formation,
although odontoblasts are abnormal and no enamel is
formed (6, 84).
Enamel knot marker genes, including cyclin-dependent
kinase inhibitor 1A (p21), Fgf4, ectodysplasin A receptor
(Edar) and Bmp4, are down-regulated in Runx2–/– lower
molars, but are expressed normally in the upper molars.
Sonic Hedgehog (Shh) is completely absent in Runx2–/–
lower molars, while weak signals remain at the tip of the
tooth bud in the upper molars (83).
Lower molars are more severely aﬀected than upper
molars in Runx2–/– mice, and incisors are less aﬀected
than molars. Hence, RUNX2 may have diﬀerent down-
stream target genes in diﬀerent regions of the jaws.
Similar regional diﬀerences in molecular regulation is
evident in relation to other genes, notably Dlx (85) and
ActivinbA (86). The diﬀerent origins of the neural crest
cells populating the maxillary and mandibular primordia
may explain their diﬀerent behavior (87). However, the
developmental proﬁles of Runx2 expression in odonto-
blasts and osteoblasts, both derived from mesenchyme, is
also diﬀerent (6), suggesting that the gene may also be
diﬀerentially regulated in these cells.
Runx2 is thus essential for tooth development up to
the bell stage, being necessary for the formation of the
enamel knot, which controls growth and folding of the
enamel organ epithelium. Whether Runx2 is essential for
the later stages of tooth development is still unknown, as
Runx2–/– mice do not survive beyond birth.
Prior to crown development, Type II Runx2 is
strongly expressed in dental papilla mesenchyme, which
gives rise to the pulpal cells and odontoblasts. Type II
Runx2 is markedly down-regulated at the bell stage in
the dental papilla, after morphogenesis is complete.
Expression continues, albeit at a lower level, in the cells
of the dental papilla, particularly near the apical por-
tion, as well as in the odontoblasts lining the pulp
chamber. Expression is evident throughout the further
development of the tooth and at all stages of root
formation, including formation of the periodontium.
Cementoblasts, cementocytes, periosteal tissue, osteo-
blasts, and osteocytes all showed expression of Type II
Runx2. No expression was found in osteoclasts. The
forming periodontium contains a decreasing gradient of
transcripts and immunostaining from crown to the root
tip (88) (Figs 7, 8).
Ameloblasts
Runx2 expression controls downstream factors acting on
the development of the enamel organ epithelium. The
importance of Runx2 in amelogenesis is evidenced by the
lack of enamel in the incisor tooth germs of Runx2–/–
mice. RUNX2 is also present in late secretory- and
maturation-stage ameloblasts (6).
AMBN is an extracellular matrix protein that may
play a role in enamel crystal formation in the developing
dentition. It is used as an ameloblast-speciﬁc gene mar-
ker. The murine Ambn promoter contains two RUNX2-
binding sites. RUNX2 interacts with functionally
important regions of the Ambn promoter, and mutations
of the Ambn promoter’s RUNX2-binding sites diminish
promoter activity. This indicates that RUNX2 possesses
an important function in transcription of the Ambn gene
(89). Runx2 Type II mRNA remains strongly expressed
in both immature and mature ameloblasts (81). Thus,
Fig. 7. Patterns of Runx2 expression. (A) Initiation stage.
Expression is induced in the mesenchyme by the odontogenic
epithelium. (B) Bud stage. Expression is maintained around the
ingrowing dental epithelium. (C) Cap stage. Expression is sus-
tained in the mesenchyme and the dental follicle. RUNX2 is
necessary for Sonic Hedgehog (Shh) expression and for for-
mation of the enamel knot. (D) Bell stage. In this stage,
expression is down-regulated in the dental papilla but is
maintained in the dental follicle and surrounding mesenchyme.
Fig. 8. Runx2 mRNA expression in the secretory stage.
Pre-ameloblasts show no expression; however, this is strongly
up-regulated in maturational phase cells. There is diﬀuse
expression throughout the dental papilla, with up-regulation in
pre-odontoblasts. Diﬀerentiated odontoblasts, however, show
no expression. The periodontal ligament shows strong expression
as do cementoblasts and cementocytes. d, dentine; e, enamel;
od, odontoblasts; ma, maturational amleoblasts; p, dental
papilla; pa, pre-amleoblasts; pdl, periodontal ligament.
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Runx2 is involved in the early stages of enamel organ
formation, and tooth morphogenesis and may also play a
direct role in formation of tooth enamel. Histological
investigation of extracted permanent teeth in CCD show
evidence of hypoplasia (90, 91). This does not appear to
be the case for deciduous teeth (92).
Odontoblasts
Osteoblasts and odontoblasts share several similarities,
including the expression of similar genes. Indeed, the
main non-collagenous components of the odontoblastic
extracellular matrix (DSPP or DMP1) are also present in
other tissues, such as osteoblasts (93) and periodontium
(94), albeit at much lower levels.
Multiple RUNX2-binding sites have been identiﬁed in
the regulatory elements of the mouse Dspp gene (66).
RUNX2 increased Dspp expression in immature odon-
toblasts, but down-regulated expression in more mature
cells, showing that the eﬀect of RUNX2 is dependent on
the state of diﬀerentiation of the target cell (95).
RUNX2 is also involved in the regulation of DMP1 in
osteoblasts, although it is not essential for DMP1
expression in odontoblasts, indicating the involvement of
other unidentiﬁed odontoblast-speciﬁc transcription
factors or co-activators (96, 97). Jiang et al. (81) found
Type III Runx2 expression in immature odontoblasts at
all stages, including cells in the dental papilla, conﬁrming
their potential to diﬀerentiate to odontoblasts.
Growth and diﬀerentiation in Runx2+/– human pri-
mary pulp cells are diﬀerent to Runx2+/+ cells as a result
of variations in gene expression patterns and signaling
(98). Therefore, the eﬀects of haploinsuﬃcency may well
inﬂuence the diﬀerentiation of odontoblasts from these
cells. Runx2 is up-regulated in early odontoblasts (99),
showing that levels of RUNX2 are necessary at this
stage. However, unlike in osteoblasts, Runx2 expression
is remarkably low or undetectable in diﬀerentiated
odontoblasts (88, 100).
This down-regulation of expression in newly diﬀeren-
tiated and functional odontoblasts suggests that Runx2
plays an essential and stage-speciﬁc role in the lineage
determination and terminal diﬀerentiation of odonto-
blasts from dental papilla mesenchyme (101). It also
highlights the diﬀerent eﬀects of this gene in diﬀerent
tissues.
Cementum
The origins of cementum-producing cells, and whether
they share common precursors with osteoblasts, are
unclear (102). Most cells embedded in the cellular
cementum express Runx2 mRNA and RUNX2 protein
to various degrees (88). As cementoblasts are mineraliz-
ing cells, this is not a surprising ﬁnding.
The result of Runx2 haploinsuﬃciency on cemental
tissue seems to vary between species. Both acellular
and cellular cementum formation is defective in per-
manent teeth in CCD subjects. This does not seem to
be the case in the deciduous teeth of CCD subjects (7,
103).
Reports on cementum formation in Runx2+/– mice are
inconsistent (104, 105). Chung et al. (105) explained the
similarity between mutant and wild-type mice in the
study of Zou et al. (104) by the mice being too young to
have developed their full root length. However, cemen-
tum formation in primary teeth in subjects with CCD
seems to be normal (92). If the mouse dentition does
represent the human primary dentition, gross abnor-
malities are not expected to be found in heterozygous
mice.
Reports of root morphology in CCD literature varies
from excessive root length (106), deformation (8,107),
and spiky (108).
Periodontal ligament
Type II Runx2 is also expressed in periodontal ligament
(PDL) ﬁbroblasts, although BSP, a marker of osteoblast
diﬀerentiation and biomineralization, is not (81). The
action of RUNX2 seems to be suppressed by a mech-
anism designed to maintain PDL width (109). The factor
S100A4 has been implicated (110).
However, these cells maintain the potential to diﬀer-
entiate to osteoblasts under certain conditions, such as
mechanical stress (111). Deformation of PDL osteoblasts
increases Runx2 expression, protein levels, and also its
DNA-binding activity, the latter possibly being caused by
activation of the ERK (extracellular signal related ki-
nase) MAPK pathway (34), although the bone response
to stress is similar in both heterozygous and wild-type
mice. Orthodontic tooth movement is not aﬀected in
Runx2 +/– mice (105); one functioning gene seems to be
suﬃcient to produce an adequate bone response.
Tooth maturation and eruption
Runx2 controls the maturation of both osteoblasts and
odontoblasts. Therefore, a delay in tooth maturation is
expected in RUNX2-deﬁcient tissues. This is reﬂected in
the clinical situation, where the dental maturation of
CCD subjects is retarded by as much as 4 years when
compared with unaﬀected subjects (8, 106, 112).
Zou et al. (104) found no diﬀerence in dental devel-
opment or eruption timing between heterozygous
knockout and wild-type mice. One functioning allele
seems to be suﬃcient for normal dental development in
the mouse. Yoda et al. (113) reached a similar conclu-
sion as regards tooth development, but found a signiﬁ-
cant diﬀerence in tooth eruption times. This was
explained as being caused by a time-speciﬁc lack of
osteoclastic response, suggesting that heterozygous mice
cannot recruit suﬃcient osteoclasts for active alveolar
bone resorption. This is essential for the prompt timing
of tooth eruption. The results also suggest the possibility
that insuﬃcient alveolar bone resorption is one of the
cellular mechanisms of the delayed tooth eruption in
CCD patients.
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The methods used in these studies are diﬀerent and
may explain the disparity in the conclusions. Further-
more, it must be pointed out that in CCD the primary
dentition is rarely aﬀected. It may be assumed that the
dentition in mice represents the human primary denti-
tion, where the eﬀects of haploinsuﬃciency on the
eruption and formation of the human dentition may be
too subtle to detect in the clinical situation. One major
shortcoming of the murine model in this respect is that
no secondary dentition develops.
Primary teeth erupt on time in CCD patients. Simi-
larly, the permanent lower incisors and ﬁrst molars
generally erupt on time. However, the subsequent per-
manent teeth exhibit a delay in eruption, presumably as a
result of defective eruption pathway formation (Fig. 1).
There does not seem to be a close correlation between the
number and positioning of supernumerary teeth and the
delay in eruption (114, 115).
Similarly, birth length in CCD children is normal, but
height drops below or around the second centile between
4 and 8 yr of age (116, 117). This pattern of development
is reﬂected in the facial morphology, the characteristic
frontal bossing and maxillary retrusion often not
becoming evident until the later stages of childhood
(118). Thus, the eﬀect of haploinsuﬃciency on the cra-
niofacial complex manifests late in a large number of
cases. Whether this is caused by variation in RUNX2
isoform levels, or simply by a greater requirement for the
gene product at that age, is unclear.
As the skeletal symptoms of CCD are not usually a
social or physical handicap, and develop late, one of the
factors leading to a diagnosis of CCD cases may be the
observed anomalies in tooth eruption leading the patient
to present for treatment (8).
Tooth eruption is controlled by precise osteoclast–
osteoblast interaction. Osteoclastogenesis in the alveolar
bone, which is essential for the accommodation of nor-
mal tooth development and eruption, is mediated by
RANK–RANKL signaling (119). The spatiotemporal
pattern and relative abundance of CSF-1, RANKL, and
OPG during tooth eruption are key determinants of site-
speciﬁc osteoclast activity in bone surrounding the tooth
(120).
Runx2 is expressed in the alveolar bone at all stages of
development and during tooth eruption (4,81). Evidence
points to RUNX2 acting, either directly or indirectly, on
the OPG/RANK/RANKL system to inﬂuence bone
remodeling. Communication takes place between tooth
germs and bone-forming/resorbing cells, synchronizing
the two processes, perhaps to ensure correct spatial
positioning of teeth in the jaws (82,121). The delayed and
ectopic eruption of teeth seen in subjects with CCD may
be caused by loss of function of RUNX2, both in respect
of reduced CSF-1 production and disruption of the
OPG/RANK/RANKL pathway.
Bone healing in CCD patients is not inﬂuenced.
Normal healing has been reported after maxillofacial
surgery (122), and osseointegration seems to be unaf-
fected (123). Deciduous teeth are extracted, and bone
is removed over unerupted teeth in order to encourage
their eruption (124). It is possible that the inﬂamma-
tory response to surgery may induce tooth eruption by
re-activation of monocyte recruitment and osteoclast
formation.
Supernumerary teeth
Supernumerary teeth are considered to be a diagnostic
feature of CCD. However, the number of supernumerary
teeth is variable, and several reports exist where no
supernumeraries exist or hypodontia is reported (125–
127).
Minor mutations in the highly conserved RHD are, in
general, more likely to produce the classic CCD pheno-
type than the more robust ﬂanking Q/A and PST
domains. The phenotype in mutations involving the
RHD is dependent on the residual transactivation
potential of the protein (126, 128).
A dose-related eﬀect seems to be present, as the milder
cases of CCD, and those exhibiting primary dental
anomalies, are associated with mutations that reduce,
but do not abolish, protein stability, DNA binding, and
transactivation. However, attempts to correlate the
number of supernumerary teeth with the severity of
skeletal symptoms are inconclusive. Furthermore, iden-
tical mutations produce diﬀerent numbers of supernu-
merary teeth (126–130). All CCD mutations, including
those which primarily feature dental anomalies, have
highly variable phenotypic expression. This may indicate
the overlying inﬂuence of other factors.
Runx2–/– and Runx2+/– mice were both found to
exhibit lingual buds in front of the upper molars, and
these were much more prominent than in wild-type mice
(84,87). Furthermore, Shh signaling was not inhibited in
the lingual buds of the knockout mice (87). Shh is
necessary for tooth formation, both in the bud and cap
stages (131), and its expression is spatially controlled to
limit it to regions of tooth development (132).
These buds presumably represent the mouse secondary
dentition, and it is likely that RUNX2 acts to inhibit
formation of these buds. It may appear contradictory
that the inhibition of RUNX2 function may arrest pri-
mary tooth development but stimulates the formation of
secondary teeth. However, it is not unusual, during
embryogenesis, for the same gene to have diﬀerent eﬀects
at diﬀerent developmental stages (87).
RUNX2 may normally function as a cell growth
inhibitor in immature osteoblasts. It acts by supporting
exit from the cell cycle, thus promoting increased
expression of the osteoblast phenotype (133). Human
Runx2 +/– pulp cells proliferate at a far greater rate than
their normal counterparts (98). This lends support to the
theory that Runx2 controls the proliferation of cells and
may exert speciﬁc control on the dental lamina and the
formation of successive dentitions.
It is easy to see how loss of function of this gene would
encourage proliferation of the dental lamina. It is also
easy to see how tooth eruption may be aﬀected. How-
ever, the lack of correlation between the loss of RUNX2
function and the number of supernumerary teeth con-
fuses matters. It is interesting to note that a mutation
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aﬀecting just the terminal VWRPY repressor motif
produced a phenotype with only mildly hypoplastic
clavicles and supernumerary teeth (5).
Concluding remarks
Runx2 is temporally and spatially regulated. The several
signaling pathways that converge on this gene, and the
existence of numerous splice variants with diﬀerent N
and C termini, substantiate its diverse actions on bone
and tooth tissues.
One eﬀect of a mutation may be to alter the propor-
tions of the splice variants of the gene which will, in turn,
aﬀect its downstream pathways by altering the levels of
interacting products. This would have diﬀerent eﬀects on
diﬀerent tissues. The inconclusive results of attempts to
correlate the number of supernumerary teeth with
eruption timing or skeletal eﬀects would support this, as
the action of RUNX2 on the dental lamina would be
diﬀerent to that on osteoblast function.
The dosage sensitivity exhibited helps to explain the
large intrafamilial variability. Genetic or epigenetic
modiﬁers may inﬂuence the phenotype, as may the
transcriptional status of the unmutated allele (126).
There exist several cases of clinically diagnosed CCD
where no mutation is detectable. Locus heterogeneity is a
possible explanation for this; however, all CCD families
tested map to the 6p21 locus (134–137).
Another explanation may be mutations within as-yet
poorly characterized intronic or regulatory sequences.
Variations in the promoter sequence point to a possible
alternative mechanism for disruption of normal RUNX2
function (138, 139). Hypermethylation of the P2 pro-
moter of the Runx3 gene severely aﬀects its function
(140, 141). Given the high homology between these
genes, the possibility of epigenetic eﬀects on the Runx2
regulatory regions should not be discounted.
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